Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer

Human Pathology

Volumn 43, Issue 10, 2012, Pages 1573-1582

  Juanpere, Nuria ^a,b   Agell, Laia ^a,b   Lorenzo, Marta ^a   De Muga, Silvia ^a,b   López Vilaró, Laura ^a,b   Murillo, Raquel ^a,b   Mojal, Sergi ^a   Serrano, Sergio ^a,b   Lorente, José A ^a,b   Lloreta, Josep ^a,c   Hernández, Silvia ^c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

AKT pathway; Bladder; Immunohistochemistry; MAPK pathway; Mutation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C H RAS; ONCOGENE K RAS; ONCOGENE RAS; PHOSPHOINOSITIDE 3 KINASE CATALYTIC ALPHA POLYPEPTIDE GENE; TRANSITIONAL CELL CARCINOMA; V AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 GENE;

CARCINOMA, TRANSITIONAL CELL; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84866499993     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.10.026     Document Type: Article

References (31)

1. D.S. Kaufman, W.U. Shipley, and A.S. Feldman Bladder cancer Lancet 374 2009 239 249
2. T.M. Morgan, K.A. Keegan, and P.E. Clark Bladder cancer Curr Opin Oncol 23 2011 275 282
3. A.A. Bakkar, H. Wallerand, and F. Radvanyi FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder Cancer Res 63 2003 8108 8112 (Pubitemid 37549454)
4. C. Billerey, D. Chopin, and M.H. Aubriot-Lorton Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 158 2001 1955 1959 (Pubitemid 32545179)
5. D. Cappellen, D.M. Gil Diez, D. Chopin, J.P. Thiery, and F. Radvanyi Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder Oncogene 14 1997 3059 3066 (Pubitemid 27336321)
6. L. Cheng, S. Zhang, G.T. MacLennan, S.R. Williamson, A. Lopez-Beltran, and R. Montironi Bladder cancer: translating molecular genetic insights into clinical practice Hum Pathol 42 2011 455 481
7. C. Cordon-Cardo p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol 22 2004 975 982
8. F. He, L. Mo, and X.Y. Zheng Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis Cancer Res 69 2009 9413 9421
9. S. Hernandez, E. Lopez-Knowles, and J. Lloreta Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas J Clin Oncol 24 2006 3664 3671 (Pubitemid 46630542)
10. M.A. Knowles Molecular pathogenesis of bladder cancer Int J Clin Oncol 13 2008 287 297
11. M.A. Knowles, F.M. Platt, and R.L. Ross Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer Cancer Metastasis Rev 28 2009 305 316
12. E. Lopez-Knowles, S. Hernandez, and M. Kogevinas The p53 pathway and outcome among patients with T1G3 bladder tumors Clin Cancer Res 12 2006 6029 6036 (Pubitemid 44703765)
13. E. Lopez-Knowles, S. Hernandez, and N. Malats PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors Cancer Res 66 2006 7401 7404 (Pubitemid 44289191)
14. A.A. Pandith, Z.A. Shah, and M.A. Siddiqi Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer Urol Oncol 2010 [Epub ahead of print.]
15. A.M. Puzio-Kuter, M. Castillo-Martin, and C.W. Kinkade Inactivation of p53 and Pten promotes invasive bladder cancer Genes Dev 23 2009 675 680
16. D.C. Tomlinson, O. Baldo, P. Harnden, and M.A. Knowles FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer J Pathol 213 2007 91 98 (Pubitemid 47354570)
17. B.W. van Rhijn, T.H. van der Kwast, and A.N. Vis FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma Cancer Res 64 2004 1911 1914 (Pubitemid 38339432)
18. D. Lindgren, A. Frigyesi, and S. Gudjonsson Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome Cancer Res 70 2010 3463 3472
19. L.C. Kompier, I. Lurkin, M.N. van der Aa, B.W. van Rhijn, T.H. van der Kwast, and E.C. Zwarthoff FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy PLoS One 5 2010 e13821
20. J.M. Askham, F. Platt, P.A. Chambers, H. Snowden, C.F. Taylor, and M.A. Knowles AKT1mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K Oncogene 29 2010 150 155
21. F.M. Platt, C.D. Hurst, C.F. Taylor, W.M. Gregory, P. Harnden, and M.A. Knowles Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer Clin Cancer Res 15 2009 6008 6017
22. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308 (Pubitemid 46480970)
23. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310 (Pubitemid 46763022)
24. E. di Martino, C.G. L'Hote, W. Kennedy, D.C. Tomlinson, and M.A. Knowles Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner Oncogene 28 2009 4306 4316
25. A.H. Jebar, C.D. Hurst, D.C. Tomlinson, C. Johnston, C.F. Taylor, and M.A. Knowles FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma Oncogene 24 2005 5218 5225 (Pubitemid 41192438)
26. R.R. Serizawa, U. Ralfkiaer, and K. Steven Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events Int J Cancer 129 2011 78 87
27. I. Boulalas, A. Zaravinos, D. Delakas, and D.A. Spandidos Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder Int J Biol Markers 24 2009 17 21
28. L. Agell, S. Hernandez, and M. Salido PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events Mod Pathol 24 2011 443 452
29. M.A. Knowles Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target World J Urol 25 2007 581 593
30. M. Karlou, A.A. Saetta, and P. Korkolopoulou Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations Pathology 41 2009 327 334
31. L. Zhao, and P.K. Vogt Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proc Natl Acad Sci USA 105 2008 2652 2657 (Pubitemid 351520568)